Neurocrine Biosciences’ (NBIX) “Buy” Rating Reaffirmed at Canaccord Genuity Group
Canaccord Genuity Group reissued their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Thursday, Benzinga reports. Canaccord Genuity Group currently has a $150.00 price target on the stock. NBIX has been the topic of several other reports. Cantor Fitzgerald reissued an overweight rating on shares of Neurocrine […]
More Stories
Why America Has a Housing Shortage Alongside an Abundance of Empty Homes
By Autumn Spredemann Homes sit empty across the United States while potential owners and renters face affordability challenges and housing...
Riots, Rates, and Risks—The Economic Roots of France’s Unrest
By Andrew Moran Unrest has gripped France as nationwide protests over the rising cost of living have swept across the...
Employer Health Insurance Costs Rise as Workers Shoulder More of the Bill, Report Says
By Bill Pan Health care costs continued to rise for employers and workers this year, with employees paying more for...
The Color Revolution Comes Home: Ex-USAID Operatives, DSA Networks, and a Playbook Aimed at the American Republic
By Stephen Zogopoulos, USNN World News In the interview titled “DataRepublican: The Democrat Plan For A Color Revolution: Everything You...
Trump Admin Can Detain Illegal Immigrants Without Bond Hearings: Appeals Court
By Zachary Stieber President Donald Trump’s administration can hold illegal immigrants in detention without bond hearings, a full federal appeals...
Florida Mayor Arrested After Authorities Say She Paid Herself and Family State COVID Funds
By Jill McLaughlin State authorities arrested the mayor of the central Florida city of Kissimmee on Oct. 21, charging her...